Zoetis Inc. $ZTS Shares Acquired by Choreo LLC

Choreo LLC increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 41.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 26,979 shares of the company’s stock after acquiring an additional 7,872 shares during the quarter. Choreo LLC’s holdings in Zoetis were worth $4,207,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at about $27,000. Saudi Central Bank purchased a new position in Zoetis during the 1st quarter worth approximately $29,000. REAP Financial Group LLC increased its position in Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after buying an additional 131 shares during the period. Finally, NewSquare Capital LLC lifted its stake in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after buying an additional 85 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Morgan Stanley decreased their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, November 10th. KeyCorp began coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Piper Sandler increased their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Finally, BTIG Research lowered their price target on Zoetis from $200.00 to $160.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, Zoetis presently has an average rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Stock Down 0.1%

ZTS stock opened at $127.78 on Thursday. The stock has a market capitalization of $56.31 billion, a PE ratio of 21.99, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company has a fifty day moving average of $136.51 and a 200-day moving average of $149.48. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. Zoetis Inc. has a one year low of $115.25 and a one year high of $181.85.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the prior year, the company posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.